Introduction
Animal Cell Technology has played an active role in providing new
diagnostic and therapeutic tools to Society. In addition to the
core knowledge developed in cell line development, protein expression,
cell physiology and engineering, and bioprocess development, the
latest advances in biology, such as the recent discoveries in stem
cells, vector development and cell line engineering, combined with
the new technologies of the genomic era, hold exceptional promises
for large advances in both the biology and bioengineering of animal
cells.
The meeting is organized into five different sessions, described
below, and abstract submission is invited for each session. The
first session is devoted to the understanding of basic cell mechanisms,
and four more sessions are devoted to the main areas of application
of cell technology. The meeting should reflect the impact of the
horizontal technologies in all these different sessions, since the
contribution from genomics and proteomics tools, physiological and
metabolic characterisation, development of expression vectors and
cell lines, cell engineering, bioprocess development and integration,
among others, will impact greatly all these different applications,
and the final success will greatly depend on the correct combination
and integration of them.
Session Description and Chairpersons
 |
|
|
|
Chairpersons: Jose Vicente Castell, Hospital La Fe,
Valencia, Spain and Mike Butler, University of Manitoba, Canada
|
|
This session addresses cellular events relevant to cell culture
technology and therapeutic applications. Cell physiology,
e.g. cell metabolism, stress response, apoptosis and proliferation
control will be covered. Emphasis is also placed on signal
transduction and control of gene expression regulation as
well as on post-transcriptional modification of proteins.
|
|
Keywords: Signal transduction, regulation of gene
expression, apoptosis, metabolism, physiology, stress response,
proliferation control, post-translational modifications
|
|
|
|
|
Concepts and new approaches for mature and stem cell based
therapies.
|
|
Chairpersons: Martin Fussenegger, ETH Zürich,
Switzerland and Eleftherios T. Papoutsakis, Northwestern University,
Evanston, USA
|
|
Advancing technologies in cell culture engineering have initiated
the concept of using cells and stem cells as therapeutic products.
The key issues are to control or reprogramme expansion and
differentiation of cell lines, mature cells, adult or embryonic
stem cells to pioneer opportunities in tissue engineering,
immune therapies, xenotransplantation and the design of three-dimensional
microtissue and artificial organs.
|
|
Keywords: Stem cells (isolation, expansion, analysis,
assays, ethics), tissue engineering, immune therapies, artificial
organs, Xenotransplantation
|
|
|
|
|
Design, production and delivery of gene based therapeutics
|
|
This session is organized in cooperation with the European
Society of Gene Therapy (ESGT).
|
|
Chairpersons: Bernd Schröder, MainGen, Frankfurt
am Main, Germany and Ernst Wagner, Ludwig-Maximilians-Universität,
Munich, Germany
|
|
Gene based technologies include vector construction, establishment
of new packaging cell lines and vaccine development. The method
of production of viral particles and vaccines influences the
final product quality, resulting in an impact in transduction
efficiency and immune response.
|
|
Keywords: Vector design, Transduction technology (delivery),
Vector/vehicle production, Vaccinology, Cell based vaccines,
Cell lines
|
|
|
|
|
Chairpersons: Hansjörg Hauser, GBF, Braunschweig,
Germany and Alain Bernard, Serono, Geneva, Switzerland
|
|
Target discovery and validation plays a crucial role in the
development of novel drugs and therapies Genomic information
together with the use of gene arrays and proteomics technologies
enables the characterisation and comparison of cells to a
previously unattained level. In this field cell culture technology
serves as an enabling tool to deliver proteins and cell lines.
These are used for gene- and structure- function analyses
and screening.
|
|
Keywords: Transcriptomics, Genomics, Proteomics, Structure,
Posttranslational modifications, High throughput bioprocessing
(culture, cell lines, expression tools, purification, analysis)
|
|
|
|
|
Improving the strategies for the production of biopharmaceuticals
|
|
Chairpersons: Carmen Vela, INGENASA, Madrid, Spain,
and Christel Fenge, AstraZeneca, Stockholm, Sweden.
|
|
This session will integrate all aspects of development and
production of recombinant proteins and anti-bodies. It covers
the development of cell lines and vectors, intracellular protein
processing, process intensification and integration, and also
addresses novel regulatory trends. The ultimate goal is to
improve quality, efficiency and time to market.
|
|
Keywords: Recombinant Proteins/MABs, Process design/intensification.
Expression (vector design, cell engineering, transient, stable),
Post-translational modifications, Process development, Regulatory,
Cell lines, Integrated processing.
|
|